We sought to examine the associations of maternal C-reactive protein (CRP) levels with fetal growth and the risks of neonatal complications.
C -reactive protein (CRP) is an acutephase reactant and a frequently used marker of low-grade systemic inflammation. Its levels increase in response to both infectious and noninfec-tious exposures. 1 Elevated CRP levels are associated with increased risks of common diseases such as cardiovascular disease and type 2 diabetes. 2, 3 However, it is still not clear whether these associations reflect causal pathways. 4, 5 Elevated CRP levels during pregnancy, as a marker of low-grade inflammation, have also been suggested to be associated with increased risks of fetal growth restriction and neonatal complications, such as preterm birth, low birthweight, and small size for gestational age (SGA). [6] [7] [8] Low-grade inflammation is associated with endothelial dysfunction, leading to vascular dysfunction and suboptimal placental development. Maternal systemic inflammation might also be a response to ischemia of the placenta, due to suboptimal placentation. 9, 10 Subsequently, suboptimal placental development might predispose mothers to increased risks for various pregnancy complications. 11, 12 Although the association of elevated CRP levels with preterm birth has been shown in several studies, results from studies relating CRP levels with fetal growth measures or neonatal complications are not consistent. 7, 8, 13, 14 Differences in results might be due to differences in study designs and populations. It is not known whether and in which trimester CRP levels affect fetal growth measures.
In a population-based prospective cohort study among 6016 pregnant women, we examined the associations of maternal CRP levels, as marker of lowgrade inflammation in early pregnancy, with fetal growth characteristics in different trimesters of pregnancy and the risks of neonatal complications.
MATERIALS AND METHODS

Design and population
This study was embedded in the Generation R Study, a population-based prospective cohort study from early fetal life onward in the city of Rotterdam, The Netherlands. 15 Enrollment was aimed in early pregnancy but was allowed until birth of the child. All mothers were enrolled from 2001 through 2005. Response rate was 61%. 15 The study was approved by the Medical Ethical Committee of the Erasmus MC, Rotterdam. Written informed consent was obtained from all participants.
Of the total of 8880 mothers who were enrolled during pregnancy, 76% (n ϭ 6748) were enrolled before a gestational age of 18 weeks. 15 Of these mothers, blood plasma samples were collected in 95% (n ϭ 6398) and CRP was successfully measured in 90% (n ϭ 6091). Mothers with extremely high CRP levels (Ͼ100 mg/L) (n ϭ 6), and mothers with twin pregnancies (n ϭ 69) were excluded, leaving 6016 mothers with singleton live births for analysis (Supplementary Figure S1 ).
High-sensitivity CRP levels
Maternal venous blood samples were collected in early pregnancy (median, 13.2; 95% range, 9.6 -17.6 weeks) and transported to the regional laboratory (Star-MDC, Rotterdam, The Netherlands) for processing and storage. 16 Blood samples were stored at Ϫ80°C. CRP concentrations were measured in EDTA plasma samples at the Department of Clinical Chemistry of the Erasmus MC in 2009. We measured high-sensitivity CRP since traditional clinically used CRP methods lack the sensitivity in low ranges needed for predicting future risk of events in apparently healthy individuals. 17 CRP levels were analyzed using an immunoturbidimetric assay on the Architect System (Abbot Diagnostics B.V., Hoofddorp, The Netherlands). The within run precision for CRP was 1.3% at 12.9 mg/L and 1.2% at 39.9 mg/L. The lowest level of detection was 0.2 mg/L. We created 6 categories of CRP levels (Ͻ5.0, 5.0-9.9, 10.0-14.9, 15.0-19.9, 20.0-24.9, and Ն25 mg/L). Levels Ͻ5.0 mg/L and Ն25 mg/L were considered as low (reference) and elevated levels, respectively.
Fetal growth characteristics
Fetal ultrasound examinations were performed in 1 of the 2 dedicated research centers in each trimester of pregnancy. Median gestational age for first, second, and third trimester visits were 12.4 weeks (95% range, 10.7-14.5), 20.5 weeks (95% range, 18.7-23.1), and 30.4 weeks (95% range, 28. 6 -32.8 ), respectively. In the second and third trimester of pregnancy, we measured fetal head circumference, abdominal circumference, and femur length to the nearest millimeter using standardized ultrasound procedures. 18 Estimated fetal weight was calculated using the formula by Hadlock et al. 19 Longitudinal growth curves and gestational age-adjusted SD scores (SDS) were constructed for all fetal growth measurements. 20 Information about offspring sex, gestational age, weight, length, and head circumference at birth was obtained from medical records and registries. Since head circumference and length at birth were not routinely measured at birth, missing birth measures were completed with data from the first-month visit at the routine child health center. Preterm birth was defined as a gestational age of Ͻ37 weeks at delivery, low birthweight was defined as birthweight Ͻ2500 g, and SGA at birth was defined as a sex-specific gestational age-adjusted birthweight below the fifth percentile in the study cohort (SDS Յ1.81 for boys and Յ1.78 for girls).
Covariates
Information about maternal educational level, ethnicity and parity was obtained by a questionnaire at enrollment in the study. Maternal smoking and alcohol consumption habits were assessed by questionnaires in each trimester. Maternal anthropometrics, including height and weight, were measured without shoes and heavy clothing and body mass index (BMI) was calculated (weight/ height 2 [kg/m 2 ]) at enrollment. 21 Maternal systolic and diastolic blood pressure were measured at intake, using standardized methods. For each participant, the mean value of 2 blood pressure readings over a 60-second interval was documented. 22 Folate levels were analyzed from venous samples drawn in the first trimester of pregnancy. Maternal age was registered at enrollment.
Statistical analysis
We assessed the associations of maternal characteristics with CRP levels as outcome levels using multivariate linear regression models. Since CRP levels were not normally distributed, we applied a logarithmic transformation for these analyses. Results are presented as geometric means (95% range) per determinant category and an overall P for trend based on these regression models. Associations of CRP levels with fetal growth characteristics were assessed using linear regression models. These models were adjusted for gestational age at the measurement, fetal sex, and maternal age, BMI, education, ethnicity, parity, smoking, alcohol consumption. BMI is known to be highly correlated with levels of CRP, 23 and with birthweight, 21,24 and therefore expected to be our main confounder. Further variables were included in these models based on their association with both the CRP levels and pregnancy outcomes, or a 10% change in the effect estimate. Next, we assessed the associations of CRP level with the risks of neonatal complications (preterm birth, low birthweight, and SGA). These models were adjusted for maternal age, BMI, education, ethnicity, parity, smoking, alcohol consumption and folic acid level at intake. Tests for trends were performed using CRP as continuous variable in multivariate linear and logistic regression analyses. The percentages of missing values within the population for analysis were Ͻ1% for continuous data and Ͻ13% for the categorical data. We applied multiple imputation for covariates. 25 Since there were no major differences in the observed results between analyses with imputed missing data or complete cases only, only results including imputed missing data are presented. All measures of association are presented with their 95% confidence intervals (CIs). All statistical analyses were performed using the SPSS, version 17.0 for Windows (SPSS Inc, Chicago, IL).
RESULTS
Maternal age ranged from 15.3-46.3 years, with a mean of 29.8 years (Table  1 ). Median CRP level was 4.5 mg/L (95% range, 0.60 -25.46). Mean offspring birthweight was 3420 g (SD 564), and median gestational age at birth was 40.1 weeks (95% range, 35.6 -42.3). Maternal education, BMI, parity, and gestational age were associated with CRP levels. Mothers with a higher parity had a higher mean CRP level (means for CRP levels from 3.84 mg/L for a parity of 0-6.15 mg/L with a parity of Ն2) and lower maternal education was associated with higher CRP levels (means for CRP levels from 5.40 mg/L for mothers with primary school only to 3.62 mg/L for mothers with higher education). A strong effect was seen for maternal BMI, with monotonous increasing means for CRP from 2.78 mg/L for the group with BMI Ͻ20 to 10.87 mg/L for the group with BMI Ն35 ( Supplementary Table S1 and Supplementary Figure S2 ).
As compared to maternal CRP levels of Ͻ5.0 mg/L, maternal CRP levels of Ն25 mg/L were inversely associated with estimated fetal weight in third trimester and with birthweight (difference Ϫ29 g, 95% CI, Ϫ58 to 0 and Ϫ128 g, 95% CI, Ϫ195 to Ϫ60, respectively). No consistent associations were observed between maternal CRP levels in early pregnancy and fetal head circumference in second or third trimester or at birth ( Table 2) . We used femur length in second and third trimester and body length at birth as fetal length measures. Maternal CRP levels were not consistently associated with fetal length. The Figure shows that, as compared to levels of Ͻ5.0 mg/L, the relative effect of CRP levels of Ն25.0 mg/L on fetal head circumference, length, and weight, presented as difference in SDS, tended to be greater at birth. All models were adjusted for maternal age, body mass index, height, systolic and diastolic blood pressure at intake, education, ethnicity, parity, smoking, alcohol, folic acid level at intake, gestational age at measurement, gestational age at blood collection, and fetal sex. CI, confidence interval.
Ernst. C-reactive protein levels in pregnancy and fetal growth. Am J Obstet Gynecol 2011. Table 3 presents both the unadjusted and adjusted associations of CRP levels with the risks of neonatal complications. The differences between the unadjusted and adjusted models were mainly explained by including maternal BMI in the models. The adjusted models show that as compared to the reference category (CRP levels Ͻ5.0 mg/L) mothers with elevated CRP levels (Ն25.0 mg/L) were more likely to deliver children with a SGA at birth (adjusted odds ratio, 2.94; 95% CI, 1.61-5.36). Mothers with elevated CRP levels (Ն25.0 mg/L) tended to be more likely to deliver preterm (adjusted odds ratio, 1.42; 95% CI, 0.69 -2.89) or a child with a low birthweight (adjusted odds ratio, 1.43; 95% CI, 0.67-3.03), as compared to the reference category, although not significantly.
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COMMENT
In this population-based prospective cohort study, we observed associations of maternal sociodemographic and anthropometric measures and lifestyle habits with CRP levels in early pregnancy. After adjustment for these variables, elevated maternal CRP levels (Ն25.0 mg/L) in early pregnancy were associated with fetal growth restriction, and increased risks of preterm birth and SGA at birth.
CRP is known to be slightly elevated during pregnancy, due to the maternal inflammatory reaction to the pregnancy. 26 Previous studies showed that measures of unhealthy lifestyle habits such as cigarette smoking are also associated with elevated CRP levels, whereas moderate alcohol consumption and increased physical activity are associated with lower CRP levels. 27-29 Increased BMI and adiposity are strongly associated with elevated CRP levels. 30, 31 In our population-based cohort among pregnant women, maternal BMI, parity, and smoking during pregnancy were all positively associated with CRP levels. Higher maternal education, European background, and continued maternal alcohol consumption were associated with lower CRP levels. Our results suggest that markers of unhealthy lifestyle habits lead to elevated CRP levels.
Our results indicate that elevated CRP levels, as a marker of maternal low-grade inflammation, are associated with fetal growth restriction. The effect estimates are relatively small. Our findings may be important from an etiological perspective or on population level. Future studies should explore the role of CRP levels in clinical practice.
We did observe an association be-
FIGURE
Elevated maternal C-reactive protein levels and fetal growth characteristics
Values are regression coefficients (95% confidence interval) and represent the difference in growth SDS between elevated levels of maternal C-reactive protein levels in early pregnancy (Ն25 mg/L) as compared to the reference group (Ͻ5.0 mg/L). All models were adjusted for maternal age, body mass index, height, systolic and diastolic blood pressure at intake, education, ethnicity, parity, smoking, alcohol, folic acid level at intake, gestational age at blood collection and fetal sex.
SDS, standard deviation score.
Ernst. C-reactive protein levels in pregnancy and fetal growth. Am J Obstet Gynecol 2011.
Research Obstetrics www.AJOG.org tween elevated maternal CRP levels in early pregnancy and the risk of SGA, which remained significant after adjustment. The differences between the unadjusted and adjusted models were mainly explained by including maternal BMI in the model. Maternal BMI is positively associated with CRP levels 32 and fetal growth. 21 After adjusting our models for maternal BMI, elevated CRP levels were still associated with fetal growth restriction and increased risks of SGA, suggest-ing that these associations are independent of maternal BMI. Our results are in line with previous smaller studies, which suggested an increased risk of preterm delivery among mothers with elevated CRP in early or mid-pregnancy. However, these studies did not demonstrate associations with fetal growth retardation. 7, 14 The mechanisms underlying these associations should further be explored, but might include that maternal lowgrade systemic inflammation, indicated by elevated CRP levels, results in suboptimal placental development, 9, 10 and subsequently increase the risks of pregnancy complications. However, higher levels of CRP may also be associated with vascular dysfunction that leads in turn to suboptimal placental development. 9, 10 Both fetal growth and pregnancy-induced hypertensive disorders might have at least part of their origin in suboptimal early placenta development. 33 Also, the associations might not reflect Adjusted odds ratios were adjusted for maternal age, body mass index, height, systolic and diastolic blood pressure at intake, education, ethnicity, parity, smoking, alcohol, folic acid level at intake, and gestational age at blood collection. CI, confidence interval.
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Obstetrics Research causality, since elevated CRP levels can be markers of other risk factors or processes leading fetal growth restriction. Previous studies focused on the associations of CRP genotypes and levels with cardiovascular disease, which used a mendelian randomization approach, suggested that CRP is not causally related to cardiovascular disease but rather a marker of other risk factors. 4, 5, 34 Such studies have not yet been performed in pregnancy. Some methodological issues need to be considered. To our knowledge, this is the largest cohort study that has examined the associations of maternal CRP levels in early pregnancy and placenta related complications in mother and child. Of all mothers enrolled in pregnancy, 76% enrolled in early pregnancy. Nonresponse at baseline would lead to selection bias if the associations would differ between those with and without complete data. This seems unlikely. Biased estimates in large cohort studies primarily arise from loss to follow-up rather than from nonresponse at baseline. 35 Since follow-up information at birth was available in 93%, we do not expect biased results due to loss to follow-up. We were able to adjust models for multiple potential confounders, related to maternal sociodemographic status, anthropometrics, and lifestyle habits. However, as in all observational studies, residual confounding due to unmeasured covariates might still be the case.
In conclusion, maternal low-grade inflammation in early pregnancy, as measured by CRP levels, was associated with fetal growth restriction and increased risks of neonatal complications. Further studies are needed to explore the underlying mechanisms and causality for these associations. Values are presented as geometric means (95% range).
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Values are based on multivariate linear regression models with adjustment for all maternal characteristics from this table.
